I. INTRODUCTION {#acm20024-sec-0001}
===============

Intensity‐modulated radiation therapy (IMRT) has been rapidly implemented in Korea due to recent governmental policy.^(^ [^1^](#acm20024-bib-0001){ref-type="ref"} ^)^ Roughly three‐fourths of all radiation treatment facilities currently perform IMRT. IMRT is capable of generating extremely precise dose distributions that provide conformal coverage of complex target shapes and conformal avoidance of sensitive normal structures.^(^ [^2^](#acm20024-bib-0002){ref-type="ref"} ^)^ The AAPM (American Association of Physicists in Medicine) and ESTRO (European Society for Therapeutic Radiology and Oncology) emphasized a comprehensive quality assurance program for clinical implementation of IMRT.^(^ [^3^](#acm20024-bib-0003){ref-type="ref"} ^,^ [^4^](#acm20024-bib-0004){ref-type="ref"} ^,^ [^5^](#acm20024-bib-0005){ref-type="ref"} ^)^ Also, the guideline of IMRT use in clinical trials has been developed throughout the world.^(^ [^6^](#acm20024-bib-0006){ref-type="ref"} ^,^ [^7^](#acm20024-bib-0007){ref-type="ref"} ^)^ AAPM Task Group 119 carried out a multi‐institutional research to assess the overall accuracy of planning and delivery of IMRT, and produced quantitative confidence limits as baseline expectation values for IMRT commissioning.^(^ [^8^](#acm20024-bib-0008){ref-type="ref"} ^)^ The British group carried out a national dosimetry audit of IMRT to provide an independent check of safe implementation and to identify problems in the modeling and delivery of IMRT.^(^ [^7^](#acm20024-bib-0007){ref-type="ref"} ^,^ [^9^](#acm20024-bib-0009){ref-type="ref"} ^--^ [^11^](#acm20024-bib-0011){ref-type="ref"} ^)^

With a rapid implementation of IMRT in Korea, ten institutions reached consensus on a multi‐institutional study to provide tolerance levels of IMRT DQA measurements as a national safety guideline for the overall accuracy of IMRT planning and delivery. The confidence limit concept and test protocol of AAPM TG‐119 were used as a basis of this study. However, the mock structures were modified according to Korean patients\' anatomy, and the dosimetry tools and phantoms used in this study were somewhat different from those of AAPM TG‐119. Furthermore, ten institutions were grouped into LINAC (seven linear accelerator‐based centers) and TOMO (three tomotherapy‐based centers), and the results of both groups were separately analyzed.

II. MATERIALS AND METHODS {#acm20024-sec-0002}
=========================

This study was performed from October 2010 to September 2011. Ten participating institutions geometrically spread over Korea were divided into the LINAC and TOMO groups. The planning and delivery systems used at each institution are summarized in Table [1](#acm20024-tbl-0001){ref-type="table-wrap"}. Both groups used 6 MV photon beams. The institutions listed in subsequent tables were anonymously identified only by letter.

###### 

List of participating institutions and the planning and delivery systems used.

  *Group*                                                                                                 *LINAC*                                                                                                                 *TOMO*                  
  -------------------- ---------------------------------- ------------------------ ---------------------- -------------------- ------------------- ------------------------- --------------------- ------------------------------ ----------------------- -----------------------------------
  Institution          Seoul Nat\'l Univ. Bundang Hosp.   Jeju Nat\'l Univ. Hosp   Yeungnam Univ. Hosp.   Dong‐A Univ. Hosp.   Eulji Univ. Hosp.   Seoul Nat\'l Univ. Hosp   Asan Medical Center   Seoul Samsung Medical Center   Yonsei Cancer Center    Chonnam Nat\'l Univ. Hwasun Hosp.
  Accelerator          Varian 21ExS                       Varian IX                Varian 21ExS           Varian Novalis       Elekta Synergy      Varian IX                 Varian Trilogy        Tomotherapy                    Tomotherapy             Tomotherapy
  Delivery Technique   DMLC                               DMLC                     DMLC                   DMLC                 SMLC                DMLC                      DMLC                  BMLC                           BMLC                    BMLC
  Planning System      Eclipse 6.5                        Eclipse 8.6              Eclipse 8.6            BrainLab iPlan       CMS Monaco 2.0.3    Eclipse 8.9               Eclipse 8.9           Tomotherapy TPS 3.1.4          Tomotherapy TPS 4.0.2   Tomotherapy TPS 3.2.3.2

$\text{DMLC} = \text{dynamic\ MLC}$; $\text{SMLC} = \text{static\ MLC}$; and $\text{BMLC} = \text{binary\ MLC}$.

A. Output and TPS audit {#acm20024-sec-0003}
-----------------------

One of the institutions has been participating in a RTOG (Radiation Therapy Oncology Group) trial and passed the RPC\'s (Radiological Physics Center. MD Anderson Cancer Center, USA) credentialing requirements. The dose audit was performed with OSLD (Optically Stimulated Luminescence Dosimeter). RPC presented that the variance of the dose determined by a single OSLD was less than 3%. The OSLD chips were irradiated at $d_{\max}$ of photon beams at 100 cm SSD (source‐to‐surface distance) in the institution and then shipped to RPC for analysis. As a result of RPC auditing, the absorbed dose measurements in good agreement were ranged from 0.98 to 1.00. This institution played the role as the reference site to indirectly verify the machine output of the other institutions through site visiting. The output was measured by skilled physicists of the reference site using a farmer type ionization chamber (0.6 cc, PTW TN30013; PTW, Freiburg, Germany) and an electrometer (PTW UNIDOS) calibrated by KRISS (Korea Research Institute of Standards and Science).

The TPS (treatment planning system) commissioning audit was carried out using two test protocols described by Van Esch et al.^(^ [^7^](#acm20024-bib-0007){ref-type="ref"} ^,^ [^12^](#acm20024-bib-0012){ref-type="ref"} ^)^ These tests were designed with three consecutive rectangular volumes that had different specified doses. The first test called a "Dip" test, for which the specified dose to the middle volume and each outer volume was 0.7 and 0.0 Gy, respectively. This test was performed for dynamic delivery to verify that the leaves could adequately shield the central volume, and the TPS modeled the transmission of the leaves correctly. The second test is called a "Step" test, for which the specified dose to each volume was 0.7, 0.5 and 0.3 Gy, respectively. The Step test was for static delivery, to test the delivered accuracy of three relative dose levels. Each institution delineated the predefined volumes for both tests on a local solid water phantom and delivered the specified doses to films (EBT2, International Specialty Products, Wayne, NJ). The reference site centrally evaluated the films from all institutions.

B. Phantom {#acm20024-sec-0004}
----------

The LINAC group used the same custom‐made phantom of acryl to measure point dose and axial plane dose distributions. The phantom of cylinder, 265 mm in length and 180 mm in diameter, has two holes where an ion chamber can be inserted. It was cut into two pieces, as shown in Fig. [1](#acm20024-fig-0001){ref-type="fig"}. The two pieces of phantom (gray and green parts in Fig. [1](#acm20024-fig-0001){ref-type="fig"}) were tightened using the lever after inserting a film in order to reduce the air gap between them. One hole at 5 cm depth below the anterior surface was used to measure a conversion factor \[nC/cGy\] of chamber reading‐to‐dose. This standard measurement was also intended to exclude the daily variation of machine output. The other hole along the axis was used to measure a planned dose in a high‐ or low‐dose and low‐gradient region. The holes were designed especially for a 0.125 cc ion chamber (Semiflex, PTW, Freiburg, Germany). For the TOMO group, the commercial phantom (i.e., 'cheese' phantom; (Accuray, Sunnyvale, CA) was used to measure point doses and coronal plane dose distributions. Details of the measurements using this phantom are described elsewhere.^(^ [^13^](#acm20024-bib-0013){ref-type="ref"} ^)^

![Developed IMRT DQA phantom for LINAC group.](ACM2-14-024-g001){#acm20024-fig-0001}

C. Mock structures {#acm20024-sec-0005}
------------------

The AAPM TG‐119 produced the mock structures for the prostate, head and neck (H&N), C‐shape, and multitarget. Each test included the targets, normal structures, planning specifications of dose goals, and beam arrangements. This study followed the general guideline of the AAPM TG‐119 programs. However, the target volumes and OAR (organs at risk) locations of the mock prostate and H&N were based on Korean patients\' anatomy.^(^ [^14^](#acm20024-bib-0014){ref-type="ref"} ^)^ The rest of the AAPM TG‐119 mock structures were identically applied for this study. All mock structures were segmented by one physicist from the reference site on DICOM CT images (DICOM, Rosslyn, VA) of both phantoms. Then these DICOM files were centrally distributed to all the institutions to eliminate any institutional variations during segmentation. It was recommended that a grid size of dose calculation used be less than 3 mm and that the calculation algorithm used be the convolution--superposition or equivalent for inhomogeneity correction.^(^ [^15^](#acm20024-bib-0015){ref-type="ref"} ^,^ [^16^](#acm20024-bib-0016){ref-type="ref"} ^)^

### C.1 Structures {#acm20024-sec-0006}

For the prostate test, the mean PTV (planning target volume) and CTV (clinical target volume) volumes of sample Korean patients were 141 cc and 50 cc, respectively. The PTV was defined to include a 1.0 cm margin around the prostate in all directions, except the posterior direction where a 0.5 cm margin was added. The rectum was a cylinder with a diameter of 1.5 cm (mean volume 10 cc) and the bladder was a semi‐ellipsoidal shape (mean volume 144 cc). The PTV included about one‐third of the rectum and bladder volumes. Unlike AAPM TG‐119, the femoral heads of spherical shape were added in this test suite. For the H&N test, the mean PTV volume of sample Korean patients was 534 cc. PTV included all anterior volume from the base of the skull to the upper neck and the posterior neck node. Both parotids were delineated with two "truncated cones" (i.e., a cone with the top cut off) of 1.5 cm diameter of a circular top and 2.4 cm diameter of a circular bottom opposing the circular bottom with 30 cc volume and located at the superior aspect of the PTV. The cord was a cylinder shape with a diameter of 1.5 cm. A gap between the cord and PTV was about 1.3 cm. For the C‐shape and multitarget tests, the AAPM TG‐119 structures were used as is. The mock structures are shown in Fig. [2](#acm20024-fig-0002){ref-type="fig"}.

![Isodose lines for low‐dose point measurement with mock structures: (a) C‐shape easy, (b) C‐shape hard, (c) H&N, (d) superior of multitarget, (e) inferior of multitarget, and (f) prostate.](ACM2-14-024-g002){#acm20024-fig-0002}

### C.2 Beam arrangements {#acm20024-sec-0007}

For the prostate and multitarget tests, the plan had seven fields at 50° intervals from the vertical (e.g., 0°, 50°, 100°, 150°, 210°, 260°, and 310°). For H&N and C‐shape tests, the plan had nine fields at 40° intervals from the vertical (e.g., 0°, 40°, 80°, 120°, 160°, 200°, 240°, 280°, and 320°).

### C.3 Dose goals {#acm20024-sec-0008}

The total prescription dose was 80 Gy (daily dose of $2\text{Gy} \times 40\text{fx}$) for the prostate test. The total prescription dose of 50 Gy (daily dose of $2\text{Gy} \times 25\text{fx}$) was applied for H&N, C‐shape, and multitarget tests. The plan goals of C‐shape were divided into easy and hard versions. The specific planning goals are shown in Table [2](#acm20024-tbl-0002){ref-type="table-wrap"}.

###### 

Treatment plan goals and results for all tests of both groups.

  *Test*            *Group*                        *LINAC*                    *TOMO*   
  ----------------- ---------- ---------- -------- --------- ------- -------- -------- -------
  Prostate          PTV D95    $> 7600$   7620.4   52.9      0.007   7788.3   166.3    0.021
                    PTV D5     $< 8400$   8267.4   188.1     0.023   8111.0   118.3    0.015
                    Rtm D30    $< 7000$   6630.6   392.4     0.059   6270.0   628.6    0.100
                    Rtm D10    $< 7500$   7324.6   208.7     0.028   7694.0   146.9    0.019
                    Bld D30    $< 7000$   5452.7   738.7     0.135   5346.7   660.3    0.124
                    Bld D10    $< 7500$   7414.8   144.8     0.020   7729.3   233.2    0.030
                    RtF D10    $< 5000$   4127.4   503.4     0.122   4171.7   926.4    0.222
                    LtF D10    $< 5000$   4014.8   504.5     0.126   4112.7   768.7    0.187
  H&N               PTV D90    5000       5052.9   84.6      0.017   4996.7   70.2     0.014
                    PTV D99    $> 4650$   4784.1   94.8      0.020   4883.3   98.7     0.020
                    PTV D20    $< 5500$   5289.6   147.2     0.028   5215.7   149.3    0.029
                    Cd max     $< 4000$   3915.0   257.5     0.066   3282.0   499.2    0.152
                    RtPd D50   $< 2000$   1916.7   160.2     0.084   1438.3   192.4    0.134
                    LtPd D50   $< 2000$   1887.3   135.3     0.072   1394.3   144.7    0.104
  C‐shape(E)        PTV D95    5000       4985.6   64.8      0.013   4982.0   19.3     0.004
                    PTV D10    $< 5500$   5463.3   188.6     0.035   5437.7   207.7    0.038
                    Core D10   $< 2500$   2446.3   145.1     0.059   1793.3   583.2    0.325
  C‐shape(H)        PTV D95    5000       4937.0   116.6     0.024   4790.7   116.8    0.024
                    PTV D10    $< 5500$   5639.4   162.7     0.029   5950.0   578.2    0.097
                    Core D10   $< 1000$   1552.9   211.9     0.136   1178.3   361.4    0.307
  Multiple‐target   Ct D99     $> 5000$   4975.6   54.0      0.011   4918.0   74.6     0.015
                    Ct D13     $< 5300$   5417.2   117.1     0.022   5852.7   1002.6   0.171
                    Sup D99    $> 2500$   2676.2   204.2     0.076   2437.3   84.5     0.035
                    Sup D13    $< 3500$   3521.3   352.0     0.100   3700.7   149.9    0.041
                    Inf D99    $> 1250$   1430.3   353.2     0.247   1220.0   60.8     0.050
                    Inf D13    $< 2500$   2593.5   607.2     0.234   3262.7   423.8    0.130

$\text{PTV} = \text{planning\ target\ volume}$; $\text{COV} = \text{coefficient}\,\text{of}\,\text{variation}$; $\text{STDV} = \text{standard}\,\text{deviation}$; $\text{Rtm} = \text{rectum}$; $\text{Bld} = \text{bladder}$; $\text{RtF} = \text{right\ femoral\ head}$; $\text{LtF} = \text{lef}t\,\text{femoral}\,\text{head}$; $\text{Cd} = \text{cord}$; $\text{RtPd} = \text{right}\,\text{parotid}$; $\text{LtPd} = \text{left}\,\text{parotid}$; $\text{Ct} = \text{central}\,\text{target}$; $\text{Sup} = \text{superior}\,\text{target}$; $\text{Inf} = \text{inferior}\,\text{target}$.

### C.4 Measurement location {#acm20024-sec-0009}

A point for high‐dose measurements was always the isocenter in the middle of PTV, where doses were high and uniform (see Fig. [3](#acm20024-fig-0003){ref-type="fig"}). A point for low‐dose measurements was located in the OAR structure such as 3 cm posterior to the rectum for the prostate, 4 cm posterior in midspinal cord for H&N, the center of cord for the C‐shape, and the center of either of two outer targets for the multitarget (see Fig. [2](#acm20024-fig-0002){ref-type="fig"}). For the per‐field measurements, a plane perpendicular to the beam axis was located at 5 cm depth in a water‐equivalent phantom with the SAD (source‐to‐axis distance) setup. The per‐field measurement was only performed for H&N test and limited to the LINAC group. A plane for the composite field measurement was across the isocenter. The plane selected for the composite field measurement often included the points for high‐ and low‐dose measurements.

![Isodose lines for high‐dose point measurements and composite field plane with mock structures: (a) C‐shape easy, (b) C‐shape hard, (c) H&N, (d) multitarget center, and (e) prostate.](ACM2-14-024-g003){#acm20024-fig-0003}

D. Point measurements {#acm20024-sec-0010}
---------------------

The LINAC group used the phantom of Fig. [1](#acm20024-fig-0001){ref-type="fig"} using a 0.125 cc ion chamber (Semiflex, PTW, Freiburg, Germany). Two sets of phantom CT images (i.e., vertical and horizontal positions) were acquired with a slice thickness of 2.5 mm. The vertical phantom images were used to calculate MUs in TPS for a conversion factor, where it was assumed that the vertical phantom at 100 cm SSD be irradiated by a $10 \times 10\,\text{cm}^{2}$ field (so‐called "standard measurements"). The horizontal phantom images were used to calculate point dose values for all tests by assuming the horizontal phantom was irradiated by all fields as planned in TPS. These planned values were compared with the measured doses. In the TOMO group, the cheese phantom was used to measure a point dose using a 0.05 cc ion chamber (Exradin A1SL, Standard Imaging Inc., Middleton, WI). The TOMO group measured an absolute dose for a standard measurement using $N_{D,W}^{C0 - 60}$ and $k_{Q}$ values. The rest of the procedure for comparison was the same as those in the LINAC group. In the low‐dose measurement, the C‐shape plan had the lowest dose in the OAR, which was expected to be at least 30 cGy. Therefore, the issue regarding very low‐dose measurements would not arise in this study.^(^ [^8^](#acm20024-bib-0008){ref-type="ref"} ^)^

E. Planar dose measurements {#acm20024-sec-0011}
---------------------------

The per‐field measurements were done by the LINAC group only for the H&N test. Each institution in the LINAC group used either a detector array or film; two institutions used MapCHECK (Sun Nuclear Corporation, Melbourne, FL); one institution used the ion chamber array (PTW, Freiburg, Germany); two institutions used MatriXX (IBA Dosimetry GmbH, Schwarzenbruck, Germany); and two institutions used EBT2 films (International Specialty Products, Wayne, NJ). The individual fields were delivered at gantry 0°. This avoided the angular dependency of detectors during per‐field measurements.^(^ [^17^](#acm20024-bib-0017){ref-type="ref"} ^,^ [^18^](#acm20024-bib-0018){ref-type="ref"} ^)^ All institutions were asked to perform the composite field measurements using films and the custom‐made (LINAC) or cheese (TOMO) phantom. The multitarget test was excluded from this measurement. The films for composite field measurement were evaluated using two gamma criteria of 2 mm DTA/2% dose difference and 3 mm DTA/3% dose difference. The planar dose distributions were normalized at a reference (dose to the isocenter) or maximum dose in a low‐gradient region. The region of interest (ROI) was first specified as a maximum size of rectangle on the film. Then any pixels that received less than 10% of the maximum dose in the dose map were excluded from the gamma evaluation. Thus, the excluded points were outside of ROI.

III. RESULTS {#acm20024-sec-0012}
============

A. Output and TPS audit {#acm20024-sec-0013}
-----------------------

The results of output audit for all participating institutions ranged from $- 1.8\%$ to $+ 2.4\%$, which indicated that all of them passed the study criteria of less than 3%. Six institutions undertook Dip and Step tests for the TPS audit, and all test plans met the required dose constraints. Four of the institutions did not perform these tests, but were requested to present the results of local TPS commission tests with film measurements. The average percentage of points passing the gamma criteria of 3 mm/3% in the Dip and Step tests were 98.2% (97.4% to 99.2%) and 97.8% (97.2% to 98.6%), respectively.

B. Planning results {#acm20024-sec-0014}
-------------------

The statistics of the mock plans for both groups are presented in Table [2](#acm20024-tbl-0002){ref-type="table-wrap"}. In this table, Dxx means the dose covering xx% of the volume. The coefficient of variation (COV) was a normalized measurement of the dispersion of a probability distribution that was defined as a ratio of the standard deviation (STDV) to the mean.

C. Point dose measurements {#acm20024-sec-0015}
--------------------------

In this study, the dose difference was expressed as a ratio of the difference between measured and planned doses to the planned dose, instead of the prescription dose used in AAPM TG‐119. The dose difference is planned according to the following equation: $$\text{Dose}\,\text{difference}(\%) = \frac{\text{Measured}\,\text{dose} - \text{Planned}\,\text{dose}}{\text{Planned}\,\text{dose}} \times 100(\%)$$

The planned dose from TPS was a value at a point of measurement for comparison. In high‐dose measurements, the average difference between measured and planned doses averaged over all tests was $- 0.7\% \pm 1.2\%$ for LINAC, $- 0.5\% \pm 1.4\%$ for TOMO, and $- 0.6\% \pm 1.3\%$ for all institutions. It ranged from $- 3.3\%$ to 1.9% for the LINAC group and from $- 2.5\%$ to 2.9% for the TOMO group. The maximum dose difference occurred in the hard C‐shape structure for both groups. The average confidence limit was 3.1% for both groups. The results of these measurements for both groups are summarized in Table [3](#acm20024-tbl-0003){ref-type="table-wrap"}.

###### 

Results of high‐dose point measurement, averaged over the institutions for LINAC/TOMO/Total groups.

  *Test*             *Mean (%)*              *STDV(%)*     *CL(%)*       *No.*
  ------------------ ----------------------- ------------- ------------- ----------
  Multitarget        $- 0.3/ - 0.2/ - 0.2$   1.0/1.8/1.2   2.3/3.6/2.5   7/3/10
  Prostate           $- 0.0/ - 0.6/ - 0.3$   1.0/1.2/1.1   1.9/3.0/2.4   7/6/13
  H&N                $- 1.0/ - 1.3/ - 1.1$   0.7/0.8/0.7   2.4/2.8/2.6   7/6/13
  C‐shape(E)         $- 1.3/0.2/ - 0.9$      1.1/1.4/1.4   3.5/3.0/3.5   7/3/10
  C‐shape(H)         $- 0.8/0.5/ - 0.4$      1.9/2.2/2.0   4.5/4.7/4.2   7/3/10
  Overall combined   $- 0.7/ - 0.5/ - 0.6$   1.2/1.4/1.3   3.1/3.2/3.1   35/21/56

$E = \text{easy}$; $H = \text{hard}$; and $\text{CL} = \text{confidence}\,\text{limit}$.

During the high‐dose measurement analysis, two institutions showed abnormal values larger than $\pm 5\%$. Both institutions were informed of these large discrepancies and they then repeated the measurements. They carefully checked the whole process and found that the conversion factor from the standard measurement was incorrect. After the correction, the results from both institutions were then less than 3%. In low‐dose measurements, the average difference between measured and planned doses averaged over all tests was $- 1.0\% \pm 1.9\%$ for LINAC group, $0.1\% \pm 2.5\%$ for TOMO group, and $- 0.6\% \pm 2.2\%$ for all institutions. It ranged from $- 6.0\%$ to 3.5% for the LINAC group and from $- 3.4\%$ to 6.6% for TOMO group. The maximum dose difference also occurred in the hard C‐shape structure for both groups. The average confidence limit was 4.9% for both groups. The results of these measurements are shown in Table [4](#acm20024-tbl-0004){ref-type="table-wrap"}. The local confidence limit of each institution, averaged over all the test plans, is listed in Table [5](#acm20024-tbl-0005){ref-type="table-wrap"}.

###### 

Results of low‐dose point measurement, averaged over the institutions for LINAC/TOMO/Total groups.

  *Test*       *Mean (%)*              *STDV(%)*     *CL(%)*       *No.*
  ------------ ----------------------- ------------- ------------- ----------
  MT (suf)     $- 0.3/1.0/0.1$         1.8/2.7/2.1   3.9/6.3/4.1   7/3/10
  MT (inf)     $- 0.5/ - 0.1/ - 0.4$   1.6/3.0/1.9   3.3/6.0/4.0   7/3/10
  Prostate     $- 1.5/ - 1.0/ - 1.2$   1.3/1.2/1.2   3.9/3.4/3.6   7/6/13
  H&N          $- 1.7/ - 0.5/ - 1.1$   0.8/2.1/1.6   3.3/4.5/4.2   7/6/13
  C‐shape(E)   $0.2/ - 0.7/ - 0.1$     2.3/2.6/2.3   4.8/5.7/4.6   7/3/10
  C‐shape(H)   $- 2.3/3.7/ - 0.5$      2.6/2.6/3.8   7.4/8.7/7.9   7/3/10
  Overall      $- 1.0/0.1/ - 0.6$      1.9/2.5/2.2   4.8/5.0/4.9   42/24/66

$\text{MT} = \text{multitarget}$; $E = \text{easy}$; $H = \text{hard}$; and $\text{CL} = \text{confidence}\,\text{limit}$.

###### 

Results of dose point measurement, averaged over all the test plans measured at each.

  *Measurement*   *Group*                                                                             *LINAC*                                           *TOMO*    
  --------------- ----------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  High Dose       Mean(%)                                               $- 1.0$   $- 1.1$   $- 0.4$   0.3       $- 1.8$   $- 0.3$   $- 0.5$   $- 1.1$   $- 0.1$   $- 0.1$
                  TDV(%)                                                0.8       1.6       1.2       0.8       1.4       0.5       1.5       1.3       1.7       1.1
                  LCL(%)[^a^](#acm20024-tbl-note-0005){ref-type="fn"}   2.6       4.3       2.7       1.9       4.5       1.2       3.4       3.6       3.4       2.3
                  No.                                                   5         5         5         5         5         5         5         7         7         7
  Low Dose        Mean(%)                                               $- 1.5$   $- 1.7$   0.4       $- 0.7$   $- 2.2$   $- 1.7$   0.4       $- 0.6$   1.1       $- 0.1$
                  STDV(%)                                               1.0       2.4       1.7       1.8       2.0       1.3       1.8       2.1       3.3       1.6
                  LCL(%)[^a^](#acm20024-tbl-note-0005){ref-type="fn"}   3.4       6.4       3.7       4.1       6.2       4.3       4.0       4.7       7.7       3.3
                  No.                                                   6         6         6         6         6         6         6         8         8         8

$\text{LCL} = \text{local}\,\text{confidence}\,\text{limit}$

D. Planar dose measurements {#acm20024-sec-0016}
---------------------------

The planar dose distributions were assessed using two gamma criteria of 2 mm/2% and 3 mm/3%. Recently, several studies reported the statistical correlation between planar IMRT QA passing rates and clinical relevance using a DVH‐based method.^(^ [^19^](#acm20024-bib-0019){ref-type="ref"} ^--^ [^22^](#acm20024-bib-0022){ref-type="ref"} ^)^ However, the current study was based on the mock structures and didn\'t intend to predict any clinical relevance with DQA results. Thus, the method for per‐field and composite field analysis coincided with the AAPM TG‐119 tolerance limit metrics using the concept of confidence limit.

### D.1 Per‐field measurements {#acm20024-sec-0017}

The per‐field measurements were done by seven institutions of the LINAC group only. The H&N test was selected for the per‐field measurements since it had the most complicated dose distributions. Each institution used an available tool such as a detector array or films. The average percentage of points passing the gamma criteria of 2 mm/2% and 3 mm/3% was $92.7\% \pm 6.5\%$ and $98.2\% \pm 2.8\%$, respectively. The corresponding confidence limit was 79.1% and 92.7% (see Table [6](#acm20024-tbl-0006){ref-type="table-wrap"}). The local confidence limit ranged from 71.4% to 95.3% for 2 mm/2% criteria and from 88.3% to 100% for 3 mm/3% criteria (Table [7](#acm20024-tbl-0007){ref-type="table-wrap"}).

###### 

Per‐field measurement: averaged percentage of points passing gamma criteria of 2 mm/2% and 3 mm/3% over the institutions.

  *Criteria*   *Mean(%)*   *STDV(%)*   *No.*   *CL(%)*
  ------------ ----------- ----------- ------- ---------
  2 mm/2%      92.7        6.5         63      79.1
  3 mm/3%      98.2        2.8         63      92.7

###### 

Per‐field measurement: local averaged percentage of points passing gamma criteria of 2 mm/2% and 3 mm/3%, with associated confidence limits.

  *Criteria*   *Institution*   *A*    *B*    *C*    *D*    *E*    *F*    *G*
  ------------ --------------- ------ ------ ------ ------ ------ ------ -------
  2 mm/2%      Mean(%)         95.2   93.0   90.5   96.3   79.1   96.8   98.1
               STDV(%)         2.9    1.7    5.4    1.0    4.0    2.7    1.5
               LCL(%)          89.4   89.7   80.0   94.4   71.4   91.5   95.3
  3 mm/3%      Mean(%)         99.4   99.3   98.0   99.0   92.4   99.0   100.0
               STDV(%)         1.0    0.5    2.1    0.9    2.1    1.3    0.0
               LCL(%)          97.4   98.3   93.9   97.2   88.3   96.5   100
               No.             9      9      9      9      9      9      9

### D.2 Composite film measurements {#acm20024-sec-0018}

The composite film measurements for all mock tests, except for the multitarget, were performed by all institutions of both groups. The TOMO group measured one additional set of tests for the prostate and H&N structures. Table [8](#acm20024-tbl-0008){ref-type="table-wrap"} summarizes the percentage of points passing the gamma criteria that was averaged over all institutions of both groups and the associated confidence limits. The gamma passing rate averaged over all mock test plans in the LINAC group was $84.7\% \pm 7.5\%$ for 2 mm/2% criteria and $94.6\% \pm 4.0\%$ for 3 mm/3% criteria. The gamma passing rate averaged over all mock test plans in the TOMO group was $88.4\% \pm 3.7\%$ for 2 mm/2% criteria and $96.4\% \pm 3.2\%$ for 3 mm/3% criteria. The gamma passing rate averaged over all mock test plans in all institutions was $86.1\% \pm 6.5\%$ for 2 mm/2% criteria and $95.3\% \pm 3.8\%$ for 3 mm/3% criteria. The TOMO group showed a higher passing rate and a lower standard deviation than the LINAC group. The local confidence limit is summarized in Table [9](#acm20024-tbl-0009){ref-type="table-wrap"}.

###### 

Composite film: percentage of points passing gamma criteria of 2 mm/2% and 3 mm/3%, with associated confidence limits for LINAC/TOMO/Total groups.

  *Criteria*   *Test*    *Prostate*       *H&N*            *C‐shape(E)*     *C‐shape(H)*     *Overall*
  ------------ --------- ---------------- ---------------- ---------------- ---------------- ----------------
  2 mm/2%      Mean(%)   86.5/88.1/87.2   85.2/86.6/85.7   85.4/92.1/88.8   81.7/88.6/83.2   84.7/88.4/86.1
               STDV(%)   6.1/2.9/4.8      7.3/0.9/5.7      8.3/7.4/8.2      9.1/3.2/8.5      7.5/3.7/6.5
               CL(%)     74.6/82.4/77.9   70.9/84.8/74.5   69.1/77.6/72.7   63.9/82.4/66.6   69.9/81.1/73.3
  3 mm/3%      Mean(%)   95.4/96.4/95.8   94.6/96.1/95.3   95.1/98.0/96.0   93.3/95.5/94.0   94.6/96.4/95.3
               STDV(%)   3.4/3.6/3.4      3.4/4.2/3.7      4.1/1.5/3.7      5.3/2.1/4.6      4.0/3.2/3.8
               CL(%)     88.7/89.3/89.2   87.9/87.8/88.0   87.1/95.1/88.7   82.9/91.3/85.0   86.8/90.0/87.9
               No.       7/6/13           7/6/13           7/3/10           7/3/10           28/18/46

###### 

Composite film: percentage of points passing gamma criteria of 2 mm/2% and 3 mm/3%, averaged over the test plans, with associated confidence limits.

  *Criteria*   *Group*                        *LINAC*                               *TOMO*   
  ------------ --------- ------ ------ ------ --------- ------ ------ ------ ------ -------- ------
  2 mm/2%      Mean      91.1   81.0   77.2   84.1      78.9   95.4   85.0   86.3   89.0     89.8
               LCL       82.6   78.5   67.7   70.6      62.6   90.4   83.2   82.0   80.8     81.8
  3 mm/3%      Mean      98.0   93.1   90.1   95.4      90.7   99.3   95.7   96.6   93.8     98.8
               STDV      1.3    0.7    3.2    3.4       4.3    0.6    1.2    3.0    2.9      1.7
               LCL       95.5   91.7   83.9   88.7      82.2   98.1   93.4   90.7   88.1     95.5
               No.       4      4      4      4         4      4      4      6      6        6

### D.3 Correlation between the magnitude of point dose error and gamma passing rates of composite field measurements {#acm20024-sec-0019}

The point dose error is an absolute value of dose difference as defined below: $$\text{Point}\,\text{dose}\,\text{error}(\%) = \left| \frac{\text{measured}\,\text{dose} - \text{Planned}\,\text{dose}}{\text{Planned}\,\text{dose}} \right| \times 100(\%)$$

Figure [4](#acm20024-fig-0004){ref-type="fig"} shows the magnitude of the point dose errors (low‐ and high‐dose measurements) versus composite field gamma passing rates (2 mm/2% and 3 mm/3%) for each test. The gamma passing rates for 2 mm/2% criteria ranged much broader than those for 3 mm/3%, while there was no significant difference in point dose errors between both criteria. However, data points for C‐shape hard cases were the most broadly dispersed, while data points for prostate case were the most closely confined. There was no stringent correlation between the magnitude of point dose errors and gamma passing rates for composite field measurements in this study.

![Magnitude of the point dose errors (low dose and high dose) vs. composite filed gamma passing rates (2 mm/2% and 3 mm/3%) for each test: (a) C‐shape easy, (b) C‐shape hard, (c) H&N, and (d) prostate.](ACM2-14-024-g004){#acm20024-fig-0004}

IV. DISCUSSION & CONCLUSION {#acm20024-sec-0020}
===========================

The multi‐institutional joint research was first performed in Korea to suggest tolerance levels for the IMRT DQA measurements. We followed the confidence limit concept presented in the AAPM TG‐119 report. Venselaar et al.^(^ [^23^](#acm20024-bib-0023){ref-type="ref"} ^)^ first suggested that the confidence limit concept was expressed with the mean value and the standard deviation (SD) multiplied by 1.5 to quantify the dose accuracy of photon beam calculations of 3D treatment planning. In AAPM TG‐119 and this study, a confidence probability $p = 0.05$ ($\left. \text{confidence}\,\text{limit} = \middle| \text{mean} + 1.96\,\text{SD} \right|$) was applied. In this study, a concept of confidence limit for the point dose measurements was appropriate metrics because of a small standard deviation and a large number of samples.^(^ [^24^](#acm20024-bib-0024){ref-type="ref"} ^)^ However, for the planar dose gamma evaluation with 2 mm/2% criteria, the concept of confidence limit was not appropriate metrics because the data including the local measurements have not only a large local deviation, but were also from a small number of samples. With 3 mm/3% criteria, it was also difficult to define the confidence limit because of a small number of samples. There was no significant difference in the tolerance levels of point dose measurements between LINAC and TOMO groups. In spite of the differences in mock structures and dosimetry tools, our tolerance levels agreed with those of AAPM and ESTRO guidelines.

The result can be used for a comparison guide of other institutions in Korea as they evaluate their IMRT commissioning and DQA results. In the near future, the domestic audit of IMRT DQA will be carried out by comparing institutional local values with the confidence limits determined by this study.
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